Who are Treatment Choice's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Placebo、CAPOX, Pf-08052666, Pf-08046045, PF-06939999 in combination with docetaxel, Pf-07921585, Pf-07220060.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/treatment-choice.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Treatment Choice — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment Choice (Treatment Choice) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Small molecule inhibitor. Area: Oncology.

marketed Small molecule inhibitor DNA repair enzyme Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Treatment Choice (Treatment Choice) — Astex Pharmaceuticals, Inc..

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Treatment Choice TARGET	Treatment Choice	Astex Pharmaceuticals, Inc.	marketed	Small molecule inhibitor	DNA repair enzyme
Placebo、CAPOX	Placebo、CAPOX	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	phase 3	chemotherapy regimen	thymidylate synthase, DNA repair enzymes
Pf-08052666	pf-08052666	Pfizer	marketed	Small molecule inhibitor	Specific protein involved in disease pathways	Unknown
Pf-08046045	pf-08046045	Pfizer	marketed	Small molecule inhibitor	Specific protein involved in cancer cell proliferation	TBD
PF-06939999 in combination with docetaxel	pf-06939999-in-combination-with-docetaxel	Pfizer	marketed	Small molecule inhibitor	Specific protein kinase	Not yet determined
Pf-07921585	pf-07921585	Pfizer	marketed	Small molecule inhibitor	Specific protein involved in cancer cell proliferation	Not available
Pf-07220060	pf-07220060	Pfizer	marketed	Small molecule inhibitor	Specific protein involved in disease pathways	Not available

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Small molecule inhibitor class)

Pfizer · 8 drugs in this class
Artcline GmbH · 1 drug in this class
Astex Pharmaceuticals, Inc. · 1 drug in this class
Rennes University Hospital · 1 drug in this class
The First Affiliated Hospital of Soochow University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Treatment Choice — Competitive Intelligence Brief. https://druglandscape.com/ci/treatment-choice. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing